Thomas Kipps

Title(s)Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Columbia College of Columbia University, New York, NYBS1974Biochemistry
    Harvard Medical School, Boston, MAPh.D.1979Immunology
    Collapse Awards and Honors
    UC San Diego School of Medicine2004Evelyn and Edwin Tasch Chair in Cancer Research

    Collapse Overview 
    Collapse Overview
    Thomas Kipps, MD, PhD, is Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research, and Deputy Director of Research Operations at the UC San Diego Moores Cancer Center. He received his Ph.D. in Immunology and M.D. from Harvard University and had his residency and fellowship training in Internal Medicine, Hematology, and Genetics at Stanford University.

    Dr. Kipps has a national and international reputation for his work in cancer research, immunology, and gene therapy. He has been a leader in the field for many years, and has helped to develop standardized treatment protocols. He is the author of more than 300 publications and is the PI on several peer-reviewed grants, including an award from NCI/NIH to fund the Chronic Lymphocytic Leukemia Research Consortium (CRC). The CRC involves collaboration with eight other Cancer Centers around the United States and the UK. Dr. Kipps is also the Director of the Blood Cancer Research Fund at the UC San Diego Moores Cancer Center. The Blood Cancer Research Fund concentrates on developing cures for all types of blood related cancers, specifically Chronic Lymphocytic Leukemia (CLL).

    Dr. Kipps has over 20 years’ experience in combining research and clinical care responsibilities. As deputy director of research operations, Dr. Kipps is working to further integrate basic and translational research investigators at the Moores Cancer Center with clinical investigators, epidemiologists, and physicians offering state-of-the art therapies for patients with various forms of cancer.

    Research Interests
    A major focus of Dr. Kipps’ research is the immunobiology and genetics of human B-cell malignancies, with emphasis on chronic lymphocytic leukemia (CLL). Dr. Kipps’ work has provided insight into the ontogeny of B cells that are subject to leukemia transformation and defined the highly restricted nature of the immunoglobulins expressed in this disease. In addition, he has defined genetic factors that contribute to the development and progression of this disease, identified biochemical pathways that enhance the growth or survival of leukemia B cells, identified means with which to elicit host anti-leukemia immune responses through vaccines generated via gene transfer, and identified promising new drugs and biologic agents that have activity in the treatment of this disease. He has made seminal observations on how the microenvironment can promote survival of CLL cells and defined strategies for mitigating the protective effects of the microenvironment on CLL cells survival in vivo. He has instigated and enabled work on selected leukemia cell samples of patients with sporadic or familial CLL that led to discovery of the role played by microRNA and ultraconserved, non-coding RNAs in the pathogenesis or progression of CLL in collaborations with the laboratory of Dr. Carlo Croce of the CLL Research Consortium (CRC). In other collaborations initiated through the CRC, Dr. Kipps also contributed to work on the epigenetic factors that contribute to pathogenesis in CLL.

    The study on CLL cells serially collected from patients at time points before therapy, during therapy, or after relapse from therapy allows for investigation of the genetic and biologic features associated with tumor progression, therapeutic response, or resistance to therapy. Discovery of features that distinguish CLL from their normal cell counterparts has helped identify new targets for therapy and/or define surrogate markers associated with more rapid rates of cancer progression or resistance to standard therapy. These studies are integrated with a clinical investigative program that attracts patients seeking improved modalities of treatment for CLL. From this, Dr. Kipps has identified molecular markers that can segregate patients into subgroups that have different risks for disease-progression or different probabilities of response to conventional treatment. This also has allowed for testing the safety and relative efficacy of novel agents developed for treatment of all patients with CLL or subgroups of patients hypothesized to have the best potential response to novel forms of therapy.

    Most recently, Dr. Kipps has discovered that the embryonic antigen ROR1 is expressed on CLL. ROR1 an embryonic type I membrane receptor tyrosine kinase-like surface protein. ROR1 was not expressed on normal, healthy adult tissues, but was found on the leukemia cells of virtually all cases of CLL and on the neoplastic cells of many patients with solid tumors. His work has demonstrated that patients immunized with autologous CLL cells transfected to express the CD40-ligand (CD154) can generate antibodies that are specific for this type I tyrosine kinase that apparently can block its capacity to function as a survival receptor for wnt5a. This work potentially could lead to development of novel vaccines for patients with this disease. Currently, Dr. Kipps is collaborating with other investigators at the UC San Diego Moores Cancer Center on developing monoclonal and recombinant antibodies specific for ROR1 and have identified one that can interfere with ROR1 signaling. The California Institute of Regenerative Medicine (CIRM) is funding this work.

    Another project undertaken in the Kipps’ lab is to define the nature of immunoglobulin gene expression in normal and neoplastic B cells and to examine the relationship between B-cell receptor signaling events and mechanisms governing the pathogenesis and/or progression of CLL. In addition he is investigating the role of the microenvironment in support both normal and neoplastic B cell survival. In addition to his laboratory research, Dr. Kipps is actively involved in clinical research; having developed and/or conducted several phase I and phase II clinical trials.

    Collapse Research 
    Collapse Research Activities and Funding
    Non-canonical Wnt-Receptor Signaling and Targeted Therapies
    NIH R01CA236361Apr 15, 2019 - Mar 31, 2024
    Role: Principal Investigator
    PCYC Karyotype
    Pharmacyclics, Inc. Jun 1, 2018 - Dec 31, 2021
    PCYC Clonal Evolution
    Pharmacyclics, Inc. Feb 21, 2018 - Feb 20, 2021
    Role: Principal Investigator
    A Phase 1b/2a Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in B-Cell Cancers
    California Institute for Regenerative Medicine (CIRM) CLIN2-10192Oct 1, 2017 - Jun 30, 2022
    Role: Principal Investigator
    Development of ROR1 CAR-T cells to target cancer stem cells in advanced malignancies
    California Institute for Regenerative Medicine (CIRM) TRAN1-10258Oct 1, 2017 - Mar 31, 2020
    Role: Co-Investigator
    Oncternal Research Agreement
    Oncternal Therapeutics, Inc. Sep 1, 2016 - Aug 31, 2021
    Role: Principal Investigator
    Oncternal Therapeutics, Inc. HRPP #140141Apr 1, 2016 - Sep 26, 2018
    Role: Principal Investigator
    ROR1 Expression in Human Breast Cancer
    Breast Cancer Research Foundation BCRF-18-123Oct 1, 2014 - Sep 30, 2019
    Role: Co-Investigator
    Protein-Coding and Non-Coding RNA Biomarkers for early detection of CLL
    MD Anderson Texas R01CA182905Jun 1, 2014 - May 31, 2019
    Role: Sub-Site Principal Investigator
    Cancer Center Support Grant (CCSG)
    NIH/NCI P30 CA23100-28May 1, 2014 - Apr 30, 2024
    Role: Senior Deputy Director, Co-Principal Investigator
    Specific Targets for Therapy of Patients with Chronic Lymphocytic Leukemia
    The Leukemia & Lymphoma Society 7005-14Oct 1, 2013 - Sep 30, 2018
    Role: Principal Investigator
    Chronic Lymphocytic Leukemia Research Consortium
    NIH/NCI 5P01CA081534-14Sep 24, 2012 - Aug 31, 2018
    Role: Principal Investigator
    Lenalidomide Treatment and the Chronic Lymphocytic Leukemia Microenvironment
    NIH R21CA135681Mar 1, 2009 - Feb 28, 2011
    Role: Principal Investigator
    Center of Nanotechnology for Treatment, Understanding, *
    NIH U54CA119335Sep 30, 2005 - Dec 31, 2011
    Role: Co-Investigator
    Antibody V Gene Expression B Cell Lymphocytic Leukemia
    NIH R37CA049870Sep 21, 2004 - Jul 31, 2015
    Role: Principal Investigator
    Chronic Lymphocytic Leukemia Research Consortium
    NIH P01CA081534May 1, 1999 - Aug 31, 2018
    Role: Principal Investigator
    CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM
    NIH P20CA081534May 1, 1999 - Apr 30, 2000
    Role: Principal Investigator
    MOLECULAR THERAPEUTICS OF RHEUMATOID ARTHRITIS
    NIH/NIAMS P50AR044850Sep 28, 1998 - Aug 31, 2004
    Role: Co-Investigator
    General Clinical Research Center
    NIH M01RR000827Jan 27, 1997 - Nov 30, 2010
    Role: Co-Investigator
    Specialized Cancer Center Support Grant
    NIH P30CA023100Jul 1, 1996 - Apr 30, 2024
    Role: Principal Investigator
    ERB 2NEU DNA VACCINES FOR BREAST CANCER IMMUNOTHERAPY
    NIH R01CA066000Sep 1, 1995 - Jun 30, 2003
    Role: Principal Investigator
    IMMUNOBIOLOGY OF AIDS LYMPHOMAS
    NIH R01CA065408Jul 25, 1994 - Jun 30, 1998
    Role: Principal Investigator
    NEW MODALITIES FOR ACTIVE IMMUNOTHERAPY OF MALIGNANCIES
    NIH R01CA057868Aug 25, 1992 - Jul 31, 1994
    Role: Principal Investigator
    NOVEL THERAPEUTIC APPROACHES IN HIV-ASSOCIATED LYMPHOMAS
    NIH R01CA055513Jul 16, 1991 - Jun 30, 1994
    Role: Principal Investigator
    MECHANISMS OF AIDS-ASSOCIATED LYMPHOMAGENESIS
    NIH R01CA054755Mar 14, 1991 - Feb 28, 1995
    Role: Principal Investigator
    ANTIBODY V GENE EXPRESSION IN HUMAN B CELL MALIGNANCIES
    NIH R01CA049870May 1, 1989 - Apr 30, 1994
    Role: Principal Investigator
    MULTIPARAMETER FLUORESCENCE ACTIVATED CELL SORTER
    NIH S10RR004051Apr 18, 1988 - Apr 17, 1990
    Role: Principal Investigator
    MULTIPURPOSE ARTHRITIS CENTER
    NIH P60AR033489Feb 1, 1987 - Jun 30, 1990
    Role: Co-Investigator
    HUMAN ANTIBODY DIVERSITY IN HEALTH &AUTOIMMUNITY
    NIH R29AR038475Aug 1, 1986 - Jul 31, 1992
    Role: Principal Investigator
    IMMUNOLOGIC AGING AND AUTOIMMUNITY
    NIH R01AG004100Jul 1, 1983 - Aug 31, 1996
    Role: Principal Investigator
    IMMUNOLOGIC AGING AND AUTOIMMUNITY
    NIH R55AG004100Jul 1, 1983 - Aug 31, 1992
    Role: Principal Investigator
    GENERAL CLINICAL RESEARCH CENTER
    NIH M01RR000833Dec 1, 1977 - Sep 30, 2005
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia mirror disease history. Cancer Discov. 2021 Jun 10. Penter L, Gohil SH, Lareau C, Ludwig LS, Parry EM, Huang T, Li S, Zhang W, Livitz D, Leshchiner I, Parida L, Getz G, Rassenti LZ, Kipps TJ, Brown JR, Davids MS, Neuberg DS, Livak KJ, Sankaran VG, Wu CJ. PMID: 34112698.
      View in: PubMed   Mentions:    Fields:    
    2. Efficacy of venetoclax plus rituximab for relapsed CLL: Five-year follow-up of continuous or limited-duration therapy. Blood. 2021 Jun 03. Ma S, Seymour JF, Brander DM, Kipps TJ, Choi MY, Anderson MA, Humphrey K, Al Masud A, Pesko J, Nandam R, Salem AH, Chyla B, Arzt J, Jacobson A, Kim SY, Roberts AW. PMID: 34115103.
      View in: PubMed   Mentions:    Fields:    
    3. Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase 1, First-in-Human Study. Clin Cancer Res. 2021 Jun 03. Davids MS, Roberts AW, Kenkre VP, Wierda WG, Kumar A, Kipps TJ, Boyer M, Salem AH, Pesko J, Arzt J, Mantas M, Kim SY, Seymour JF. PMID: 34083230.
      View in: PubMed   Mentions:    Fields:    
    4. Exploring the Pathways to Chronic Lymphocytic Leukemia. Blood. 2021 Jun 01. Stevenson FK, Forconi F, Kipps TJ. PMID: 34075408.
      View in: PubMed   Mentions:    Fields:    
    5. miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. Blood. 2021 May 06; 137(18):2481-2494. Sharma S, Pavlasova GM, Seda V, Cerna KA, Vojackova E, Filip D, Ondrisova L, Sandova V, Kostalova L, Zeni PF, Borsky M, Oppelt J, Liskova K, Kren L, Janikova A, Pospisilova S, Fernandes SM, Shehata M, Rassenti LZ, Jaeger U, Doubek M, Davids MS, Brown JR, Mayer J, Kipps TJ, Mraz M. PMID: 33171493.
      View in: PubMed   Mentions: 6     Fields:    
    6. Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2021 Mar 18. Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, Jones D, Izumi R, Frigault MM, Quah C, Raman RK, Patel P, Wang MH, Kipps TJ. PMID: 33730844.
      View in: PubMed   Mentions: 1     Fields:    
    7. A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell. 2021 Mar 08; 39(3):380-393.e8. Lazarian G, Yin S, Ten Hacken E, Sewastianik T, Uduman M, Font-Tello A, Gohil SH, Li S, Kim E, Joyal H, Billington L, Witten E, Zheng M, Huang T, Severgnini M, Lefebvre V, Rassenti LZ, Gutierrez C, Georgopoulos K, Ott CJ, Wang L, Kipps TJ, Burger JA, Livak KJ, Neuberg DS, Baran-Marszak F, Cymbalista F, Carrasco RD, Wu CJ. PMID: 33689703.
      View in: PubMed   Mentions:    Fields:    
    8. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. Leuk Res. 2021 03; 102:106520. Solman IG, Blum LK, Burger JA, Kipps TJ, Dean JP, James DF, Mongan A. PMID: 33611131.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    9. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. J Hematol Oncol. 2021 01 15; 14(1):17. Walker JS, Hing ZA, Harrington B, Baumhardt J, Ozer HG, Lehman A, Giacopelli B, Beaver L, Williams K, Skinner JN, Cempre CB, Sun Q, Shacham S, Stromberg BR, Summers MK, Abruzzo LV, Rassenti L, Kipps TJ, Parikh S, Kay NE, Rogers KA, Woyach JA, Coppola V, Chook YM, Oakes C, Byrd JC, Lapalombella R. PMID: 33451349.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    10. Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discov. 2021 Jan; 2(1):54-69. Kretzmer H, Biran A, Purroy N, Lemvigh C, Clement K, Gruber M, Gu H, Rassenti L, Mohammad AW, Lesnick C, Slager SL, Braggio E, Shanafelt TD, Kay NE, Fernandes S, Brown JR, Wang L, Li S, Livak KJ, Neuberg DS, Klages S, Timmermann B, Kipps TJ, Campo E, Gnirke A, Wu CJ, Meissner A. PMID: 33604581.
      View in: PubMed   Mentions:
    11. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism. Leukemia. 2021 Jun; 35(6):1621-1630. Hasan MK, Ghia EM, Rassenti LZ, Widhopf GF, Kipps TJ. PMID: 33097837.
      View in: PubMed   Mentions: 1     Fields:    
    12. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J Clin Oncol. 2020 12 01; 38(34):4042-4054. Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Dubois J, Eldering E, Mellink C, Van Der Kevie-Kersemaekers AM, Kim SY, Chyla B, Punnoose E, Bolen CR, Assaf ZJ, Jiang Y, Wang J, Lefebure M, Boyer M, Humphrey K, Seymour JF. PMID: 32986498.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    13. Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 09 16; 12(561). Bachireddy P, Ennis C, Nguyen VN, Gohil SH, Clement K, Shukla SA, Forman J, Barkas N, Freeman S, Bavli N, Elagina L, Leshchiner I, Mohammad AW, Mathewson ND, Keskin DB, Rassenti LZ, Kipps TJ, Brown JR, Getz G, Ho VT, Gnirke A, Neuberg D, Soiffer RJ, Ritz J, Alyea EP, Kharchenko PV, Wu CJ. PMID: 32938797.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020 09; 21(9):1188-1200. Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Tausch E, Schary W, Ritgen M, Wendtner CM, Kreuzer KA, Eichhorst B, Stilgenbauer S, Hallek M, Fischer K. PMID: 32888452.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    15. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2020 10; 97:106432. Solman IG, Blum LK, Hoh HY, Kipps TJ, Burger JA, Barrientos JC, O'Brien S, Mulligan SP, Kay NE, Hillmen P, Byrd JC, Lal ID, Dean JP, Mongan A. PMID: 32911375.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsCTClinical Trials
    16. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 02; 18(2):185-217. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar H. PMID: 32023533.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    17. Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis. Oncogene. 2020 03; 39(12):2550-2567. Zhang J, Lin X, Wu L, Huang JJ, Jiang WQ, Kipps TJ, Zhang S. PMID: 31996785.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    18. NF-?B-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia. Cell Death Differ. 2020 07; 27(7):2206-2216. Sanchez-Lopez E, Ghia EM, Antonucci L, Sharma N, Rassenti LZ, Xu J, Sun B, Kipps TJ, Karin M. PMID: 31992855.
      View in: PubMed   Mentions: 5     Fields:    
    19. Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study. J Hematol Oncol. 2019 11 19; 12(1):114. Ramassone A, D'Argenio A, Veronese A, Basti A, Soliman SHA, Volinia S, Bassi C, Pagotto S, Ferracin M, Lupini L, Saccenti E, Balatti V, Pepe F, Rassenti LZ, Innocenti I, Autore F, Marzetti L, Mariani-Costantini R, Kipps TJ, Negrini M, Laurenti L, Visone R. PMID: 31744508.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    20. Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2019 11 26; 116(48):24252-24258. Veneziano D, Tomasello L, Balatti V, Palamarchuk A, Rassenti LZ, Kipps TJ, Pekarsky Y, Croce CM. PMID: 31723042.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    21. Targeted Therapy in Chronic Lymphocytic Leukemia. Cancer J. 2019 Nov/Dec; 25(6):378-385. Kipps TJ, Choi MY. PMID: 31764118.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    22. Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis. NPJ Breast Cancer. 2019; 5:35. Hasan MK, Widhopf GF, Zhang S, Lam SM, Shen Z, Briggs SP, Parker BA, Kipps TJ. PMID: 31667337.
      View in: PubMed   Mentions:
    23. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020 03; 34(3):787-798. Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ. PMID: 31628428.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    24. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019 12; 94(12):1353-1363. Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. PMID: 31512258.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    25. Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia. Target Oncol. 2019 10; 14(5):551-561. Udd KA, Bujarski S, Wirtschafter E, Spektor TM, Ghermezi M, Rassenti LZ, David ME, Nosrati JD, Rahbari AA, Wang J, Vardanyan S, Harutyunyan NM, Linesch J, Li M, Sanchez E, Chen H, Kipps TJ, Berenson JR. PMID: 31473933.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    26. A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica. 2020 04; 105(4):e164-e168. Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JG. PMID: 31413095.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-?B to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019 09 26; 134(13):1084-1094. Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, Zhang S, Sanchez-Lopez E, Widhopf GF, Messer K, Rassenti LZ, Jamieson C, Kipps TJ. PMID: 31409670.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    28. A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(14):3461-3469. Andritsos LA, Byrd JC, Cheverton P, Wu J, Sivina M, Kipps TJ, Burger JA. PMID: 31352850.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    29. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 11; 19(11):715-722.e6. Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, Byrd JC, O'Brien SM, Dilhuydy MS, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan AA, Mahler M, Salman M, Eckert K, Solman IG, Balasubramanian S, Cheng M, Londhe A, Ninomoto J, Howes A, James DF, Hallek M. PMID: 31447270.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    30. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood. 2019 08 22; 134(8):688-698. Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC. PMID: 31292113.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    31. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 06 25; 3(12):1799-1807. Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. PMID: 31196847.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    32. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019 Jun 06; 380(23):2225-2236. Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. PMID: 31166681.
      View in: PubMed   Mentions: 105     Fields:    Translation:Humans
    33. SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):321-325. Choi MY, Wang HY, Kipps TJ. PMID: 31204237.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    34. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019 06; 570(7762):474-479. Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, Neuberg D, Kipps TJ, Nowak MA, Getz G, Wu CJ. PMID: 31142838.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    35. Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels. Haematologica. 2020 01; 105(1):e22-e25. Lujan JV, Lengerke-Diaz PA, Jacobs C, Moreno-Cortes EF, Ramirez-Segura CA, Choi MY, McCarthy C, Heinen A, Kipps TJ, Castro JE. PMID: 31048356.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    36. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019 07 11; 134(2):111-122. Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF. PMID: 31023700.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    37. HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia. Cancers (Basel). 2019 Apr 23; 11(4). Pagotto S, Veronese A, Soranno A, Balatti V, Ramassone A, Guanciali-Franchi PE, Palka G, Innocenti I, Autore F, Rassenti LZ, Kipps TJ, Mariani-Costantini R, Laurenti L, Croce CM, Visone R. PMID: 31018621.
      View in: PubMed   Mentions:
    38. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 06 01; 37(16):1391-1402. Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S. PMID: 30995176.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    39. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 04 09; 3(7):1167-1174. Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR. PMID: 30967392.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    40. Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia. Blood. 2019 06 20; 133(25):2651-2663. Ghia EM, Rassenti LZ, Neuberg DS, Blanco A, Yousif F, Smith EN, McPherson JD, Hudson TJ, HALT Pan-Leukemia Gene Panel Consortium , Harismendy O, Frazer KA, Kipps TJ. PMID: 30923040.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    41. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019 06 27; 133(26):2765-2775. Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ. PMID: 30862645.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    42. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol. 2019 05; 94(5):554-562. O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA. PMID: 30767298.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    43. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019 05 09; 133(19):2031-2042. Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR. PMID: 30842083.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    44. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2019 07; 186(1):184-188. Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS. PMID: 30740654.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    45. A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. Cancer Cell. 2019 02 11; 35(2):283-296.e5. Yin S, Gambe RG, Sun J, Martinez AZ, Cartun ZJ, Regis FFD, Wan Y, Fan J, Brooks AN, Herman SEM, Ten Hacken E, Taylor-Weiner A, Rassenti LZ, Ghia EM, Kipps TJ, Obeng EA, Cibulskis CL, Neuberg D, Campagna DR, Fleming MD, Ebert BL, Wiestner A, Leshchiner I, DeCaprio JA, Getz G, Reed R, Carrasco RD, Wu CJ, Wang L. PMID: 30712845.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    46. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. Proc Natl Acad Sci U S A. 2019 01 22; 116(4):1370-1377. Zhang S, Zhang H, Ghia EM, Huang J, Wu L, Zhang J, Lam S, Lei Y, He J, Cui B, Widhopf GF, Yu J, Schwab R, Messer K, Jiang W, Parker BA, Carson DA, Kipps TJ. PMID: 30622177.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    47. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. J Natl Compr Canc Netw. 2019 Jan; 17(1):12-20. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H. PMID: 30659125.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    48. Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL. Blood. 2019 02 28; 133(9):990-992. Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Hirata J, McIver T, Morariu-Zamfir R, Kipps TJ. PMID: 30593446.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    49. Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells. Leukemia. 2019 03; 33(3):653-661. Hasan MK, Rassenti L, Widhopf GF, Yu J, Kipps TJ. PMID: 30568170.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    50. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2019 02 01; 37(4):269-277. Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ. PMID: 30523712.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCTClinical Trials
    51. SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia. Br J Haematol. 2019 02; 184(4):605-615. Brander DM, Friedman DR, Volkheimer AD, Christensen DJ, Rassenti LZ, Kipps TJ, Guadalupe E, Chen Y, Zhang D, Wang X, Davis C, Owzar K, Weinberg JB. PMID: 30443898.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    52. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. Am J Hematol. 2018 11; 93(11):1402-1410. Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P. PMID: 30129285.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    53. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19). Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, Ghia EM, Kim E, Rassenti LZ, Burger JA, Kipps TJ, Meyerson ML, Bachireddy P, Wang L, Reed R, Neuberg D, Carrasco RD, Brooks AN, Letai A, Davids MS, Wu CJ. PMID: 30282833.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    54. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leuk Lymphoma. 2019 04; 60(4):1000-1005. Barrientos JC, Burger JA, Byrd JC, Hillmen P, Zhou C, Ninomoto J, James DF, Kipps TJ. PMID: 30277101.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    55. miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood. 2018 11 15; 132(20):2179-2182. Balatti V, Tomasello L, Rassenti LZ, Veneziano D, Nigita G, Wang HY, Thorson JA, Kipps TJ, Pekarsky Y, Croce CM. PMID: 30242085.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    56. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018 09; 103(9):1502-1510. Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P. PMID: 29880603.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    57. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018 Jun 01; 22(6):951-959.e3. Choi MY, Widhopf GF, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E, Pu M, Messer K, Prussak CE, Castro JE, Jamieson C, Kipps TJ. PMID: 29859176.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCellsCTClinical Trials
    58. Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget. 2018 May 15; 9(37):24731-24736. Yu J, Chen Y, Chen L, Zhang L, Rassenti LZ, Widhopf GF, Kipps TJ. PMID: 29872501.
      View in: PubMed   Mentions: 9     Fields:    
    59. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol. 2018 05 01; 4(5):712-716. O'Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE. PMID: 29470582.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    60. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood. 2018 07 12; 132(2):170-178. Hasan MK, Yu J, Widhopf GF, Rassenti LZ, Chen L, Shen Z, Briggs SP, Neuberg DS, Kipps TJ. PMID: 29678828.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    61. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018 Mar 22; 378(12):1107-1120. Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP. PMID: 29562156.
      View in: PubMed   Mentions: 156     Fields:    Translation:HumansCTClinical Trials
    62. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 06 21; 131(25):2745-2760. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. PMID: 29540348.
      View in: PubMed   Mentions: 200     Fields:    Translation:Humans
    63. Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry. Cell Rep. 2018 02 13; 22(7):1875-1888. Gonzalez VD, Samusik N, Chen TJ, Savig ES, Aghaeepour N, Quigley DA, Huang YW, Giangarrà V, Borowsky AD, Hubbard NE, Chen SY, Han G, Ashworth A, Kipps TJ, Berek JS, Nolan GP, Fantl WJ. PMID: 29444438.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    64. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):114-124.e2. Mato A, Nabhan C, Kay NE, Lamanna N, Kipps TJ, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Kiselev P, Swern AS, Bhushan S, Sullivan K, Flick ED, Sharman JP. PMID: 29352719.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsCTClinical Trials
    65. Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2018 06; 103(6):e249-e251. Coutre S, Tedeschi A, Robak T, Barr PM, Owen C, Bairey O, Burger J, Zhou C, Styles L, James DF, Kipps TJ. PMID: 29170253.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    66. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 11; 15(11):1414-1427. Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H. PMID: 29118233.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    67. Corrigendum to "Wnt5a Signaling in Normal and Cancer Stem Cells". Stem Cells Int. 2017; 2017:3467360. Zhou Y, Kipps TJ, Zhang S. PMID: 29098008.
      View in: PubMed   Mentions:
    68. MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2017 10 03; 114(40):10731-10736. Rassenti LZ, Balatti V, Ghia EM, Palamarchuk A, Tomasello L, Fadda P, Pekarsky Y, Widhopf GF, Kipps TJ, Croce CM. PMID: 28923920.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    69. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 10; 102(10):1796-1805. Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA. PMID: 28751558.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    70. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. J Hematol Oncol. 2017 05 19; 10(1):112. Kashyap MK, Amaya-Chanaga CI, Kumar D, Simmons B, Huser N, Gu Y, Hallin M, Lindquist K, Yafawi R, Choi MY, Amine AA, Rassenti LZ, Zhang C, Liu SH, Smeal T, Fantin VR, Kipps TJ, Pernasetti F, Castro JE. PMID: 28526063.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    71. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget. 2017 Apr 18; 8(16):25942-25954. Miller CR, Ruppert AS, Fobare S, Chen TL, Liu C, Lehman A, Blachly JS, Zhang X, Lucas DM, Grever MR, Tallman MS, Flinn IW, Rassenti LZ, Kipps TJ, Sampath D, Coombes KR, Hertlein EK. PMID: 28412730.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    72. Wnt5a Signaling in Normal and Cancer Stem Cells. Stem Cells Int. 2017; 2017:5295286. Zhou Y, Kipps TJ, Zhang S. PMID: 28491097.
      View in: PubMed   Mentions:
    73. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017 07; 178(2):286-291. Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM. PMID: 28397242.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    74. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017 05 11; 129(19):2702-2705. Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, López J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJM, Böttcher S, Ritgen M, Goede V, Mobasher M, Hallek M. PMID: 28325865.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    75. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 02 09; 3:17008. Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K. PMID: 28179635.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    76. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 01 19; 3:16096. Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K. PMID: 28102226.
      View in: PubMed   Mentions: 97     Fields:    Translation:Humans
    77. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017 Mar 10; 35(8):826-833. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF. PMID: 28095146.
      View in: PubMed   Mentions: 154     Fields:    Translation:Humans
    78. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017 Feb; 18(2):230-240. Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW. PMID: 28089635.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    79. hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents. ACS Chem Biol. 2017 02 17; 12(2):444-455. Barile E, Marconi GD, De SK, Baggio C, Gambini L, Salem AF, Kashyap MK, Castro JE, Kipps TJ, Pellecchia M. PMID: 28026162.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    80. Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. Br J Haematol. 2016 Dec; 175(5):892-903. Mato A, Nabhan C, Kay NE, Weiss MA, Lamanna N, Kipps TJ, Grinblatt DL, Flinn IW, Kozloff MF, Flowers CR, Farber CM, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP. PMID: 27861736.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    81. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016 12 22; 128(25):2931-2940. Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, Yu J, Neuberg DS, Wierda WG, Rai KR, Kay NE, Brown JR, Jones JA, Gribben JG, Frazer KA, Kipps TJ. PMID: 27815263.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    82. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell. 2016 Nov 14; 30(5):750-763. Wang L, Brooks AN, Fan J, Wan Y, Gambe R, Li S, Hergert S, Yin S, Freeman SS, Levin JZ, Fan L, Seiler M, Buonamici S, Smith PG, Chau KF, Cibulskis CL, Zhang W, Rassenti LZ, Ghia EM, Kipps TJ, Fernandes S, Bloch DB, Kotliar D, Landau DA, Shukla SA, Aster JC, Reed R, DeLuca DS, Brown JR, Neuberg D, Getz G, Livak KJ, Meyerson MM, Kharchenko PV, Wu CJ. PMID: 27818134.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCells
    83. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol. 2018 02; 180(4):597-600. Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda WG, Keating MJ, O'Brien S, Neuberg D, Kipps T, Burger JA. PMID: 27766619.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    84. How Do Targeted Therapies Change the Management of Indolent Lymphomas? Oncology (Williston Park). 2016 09 15; 30(9):859-60. Choi MY, Kipps TJ. PMID: 27633418.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    85. Upregulation of long noncoding RNA MIAT in aggressive form of chronic lymphocytic leukemias. Oncotarget. 2016 08 23; 7(34):54174-54182. Sattari A, Siddiqui H, Moshiri F, Ngankeu A, Nakamura T, Kipps TJ, Croce CM. PMID: 27527866.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    86. Adoptive cellular therapy for chronic lymphocytic leukemia and B cell malignancies. CARs and more. Best Pract Res Clin Haematol. 2016 03; 29(1):15-29. Castro JE, Kipps TJ. PMID: 27742068.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    87. Selectivity in Small Molecule Splicing Modulation. ACS Chem Biol. 2016 10 21; 11(10):2716-2723. Kumar D, Kashyap MK, La Clair JJ, Villa R, Spaanderman I, Chien S, Rassenti LZ, Kipps TJ, Burkart MD, Castro JE. PMID: 27499047.
      View in: PubMed   Mentions: 8     Fields:    Translation:Cells
    88. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016 09 22; 128(12):1609-13. Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, Mayer J, Calogero R, Trbusek M, Pospisilova S, Davids MS, Kipps TJ, Brown JR, Mraz M. PMID: 27480113.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    89. ATM Mutations in Cancer: Therapeutic Implications. . 2016 08; 15(8):1781-91. Choi M, Kipps T, Kurzrock R. PMID: 27413114.
      View in: PubMed   Mentions:
    90. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leuk Lymphoma. 2017 02; 58(2):348-356. Jewell RC, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Smolej L, Mayer J, Hess G, Hernandez-Ilizaliturri FJ, Padmanabhan-Iyer S, Fang L, Goldstein N, Gorczyca M, Gupta I, Lisby S, Wierda WG, Hx-CD20-407 Study Investigators . PMID: 27389174.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    91. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203. Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, Hanna J, Ritz J, Kim HT, Brown JR. PMID: 27247136.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansCTClinical Trials
    92. Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2016 07; 101(7):e295-8. Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ. PMID: 27151992.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    93. Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations. Int J Hematol Oncol. 2016 May; 5(1):27-35. Manouchehri S, Ibsen S, Wright J, Rassenti L, Ghia EM, Widhopf GF, Kipps TJ, Heller MJ. PMID: 30302201.
      View in: PubMed   Mentions:
    94. The Cell Surface Receptor CD44: NMR-Based Characterization of Putative Ligands. ChemMedChem. 2016 05 19; 11(10):1097-106. Baggio C, Barile E, Di Sorbo G, Kipps TJ, Pellecchia M. PMID: 27144715.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    95. Ibrutinib for Chronic Lymphocytic Leukemia. N Engl J Med. 2016 04 21; 374(16):1594-5. Burger JA, Styles L, Kipps TJ. PMID: 27096594.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    96. Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer. Proc Natl Acad Sci U S A. 2016 May 03; 113(18):5071-6. Pekarsky Y, Balatti V, Palamarchuk A, Rizzotto L, Veneziano D, Nigita G, Rassenti LZ, Pass HI, Kipps TJ, Liu CG, Croce CM. PMID: 27071132.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    97. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. Br J Haematol. 2016 Apr; 173(1):105-13. Van Dyke DL, Werner L, Rassenti LZ, Neuberg D, Ghia E, Heerema NA, Dal Cin P, Dell Aquila M, Sreekantaiah C, Greaves AW, Kipps TJ, Kay NE. PMID: 26848054.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    98. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016 Feb; 126(2):585-98. Yu J, Chen L, Cui B, Widhopf GF, Shen Z, Wu R, Zhang L, Zhang S, Briggs SP, Kipps TJ. PMID: 26690702.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimalsCells
    99. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016 Jan 19; 7(3):2809-22. Kashyap MK, Kumar D, Jones H, Amaya-Chanaga CI, Choi MY, Melo-Cardenas J, Ale-Ali A, Kuhne MR, Sabbatini P, Cohen LJ, Shelat SG, Rassenti LZ, Kipps TJ, Cardarelli PM, Castro JE. PMID: 26646452.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    100. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet. 2016 Mar; 48(3):253-64. Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, Wang Q, Imbusch CD, Serva A, Koser SD, Brocks D, Lipka DB, Bogatyrova O, Weichenhan D, Brors B, Rassenti L, Kipps TJ, Mertens D, Zapatka M, Lichter P, Döhner H, Küppers R, Zenz T, Stilgenbauer S, Byrd JC, Plass C. PMID: 26780610.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansCells
    101. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma. 2016; 57(6):1291-9. Wendtner CM, Hallek M, Fraser GA, Michallet AS, Hillmen P, Dürig J, Kalaycio M, Gribben JG, Stilgenbauer S, Buhler A, Kipps TJ, Purse B, Zhang J, De Bedout S, Mei J, Chanan-Khan A. PMID: 26763349.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    102. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015 Dec 17; 373(25):2425-37. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ, RESONATE-2 Investigators . PMID: 26639149.
      View in: PubMed   Mentions: 357     Fields:    Translation:HumansCTClinical Trials
    103. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28; 374(4):311-22. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF. PMID: 26639348.
      View in: PubMed   Mentions: 498     Fields:    Translation:HumansCTClinical Trials
    104. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17; 126(25):2686-94. O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. PMID: 26472751.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCTClinical Trials
    105. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2016 Jan 07; 127(1):79-86. Byrd JC, Flynn JM, Kipps TJ, Boxer M, Kolibaba KS, Carlile DJ, Fingerle-Rowson G, Tyson N, Hirata J, Sharman JP. PMID: 26472752.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    106. Quaking and miR-155 interactions in inflammation and leukemogenesis. Oncotarget. 2015 Sep 22; 6(28):24599-610. Tili E, Chiabai M, Palmieri D, Brown M, Cui R, Fernandes C, Richmond T, Kim T, Sheetz T, Sun HL, Lagana A, Veneziano D, Volinia S, Rassenti L, Kipps T, Awad H, Michaille JJ, Croce CM. PMID: 26337206.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    107. An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(10):2819-25. Patton WN, Lindeman R, Butler AC, Kipps TJ, Jewell RC, Laubscher KH, Zhou YY, Lewis E, Sedoti D, Witman P, Fang L, Chan G. PMID: 25721750.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    108. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. PMID: 26211600.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    109. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S167-9. Choi MY, Widhopf GF, Wu CC, Cui B, Lao F, Sadarangani A, Cavagnaro J, Prussak C, Carson DA, Jamieson C, Kipps TJ. PMID: 26297272.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    110. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations. PLoS One. 2015; 10(6):e0128151. Deniger DC, Yu J, Huls MH, Figliola MJ, Mi T, Maiti SN, Widhopf GF, Hurton LV, Thokala R, Singh H, Olivares S, Champlin RE, Wierda WG, Kipps TJ, Cooper LJ. PMID: 26030772.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    111. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(10):2826-33. Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil IS, Yalamanchili S, Chai A, Sahasranaman S, Punnoose E, Hurst D, Pylypenko H. PMID: 25797560.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCTClinical Trials
    112. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. . 2015 Jul; 14(7):1650-60. Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, Aviña H, Karki S, Abad JD, Yang P, Moon SJ, Malik F, Choi MY, An Z, Morrison K, Challita-Eid PM, Doñate F, Joseph IB, Kipps TJ, Dick JE, Stover DR. PMID: 25934707.
      View in: PubMed   Mentions:
    113. Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine. 2015 Jun; 2(6):572-82. Ferrajoli A, Ivan C, Ciccone M, Shimizu M, Kita Y, Ohtsuka M, D'Abundo L, Qiang J, Lerner S, Nouraee N, Rabe KG, Rassenti LZ, Van Roosbroeck K, Manning JT, Yuan Y, Zhang X, Shanafelt TD, Wierda WG, Sabbioni S, Tarrand JJ, Estrov Z, Radovich M, Liang H, Negrini M, Kipps TJ, Kay NE, Keating M, Calin GA. PMID: 26288818.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    114. Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development. Blood Cancer J. 2015 Apr 10; 5:e303. Smith EN, Ghia EM, DeBoever CM, Rassenti LZ, Jepsen K, Yoon KA, Matsui H, Rozenzhak S, Alakus H, Shepard PJ, Dai Y, Khosroheidari M, Bina M, Gunderson KL, Messer K, Muthuswamy L, Hudson TJ, Harismendy O, Barrett CL, Jamieson CH, Carson DA, Kipps TJ, Frazer KA. PMID: 25860294.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    115. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B. Haematologica. 2015 Jul; 100(7):945-54. Kashyap MK, Kumar D, Villa R, La Clair JJ, Benner C, Sasik R, Jones H, Ghia EM, Rassenti LZ, Kipps TJ, Burkart MD, Castro JE. PMID: 25862704.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    116. Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2015 Apr 07; 112(14):4322-7. Blachly JS, Ruppert AS, Zhao W, Long S, Flynn J, Flinn I, Jones J, Maddocks K, Andritsos L, Ghia EM, Rassenti LZ, Kipps TJ, de la Chapelle A, Byrd JC. PMID: 25787252.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    117. Transcriptome sequencing reveals potential mechanism of cryptic 3' splice site selection in SF3B1-mutated cancers. PLoS Comput Biol. 2015 Mar; 11(3):e1004105. DeBoever C, Ghia EM, Shepard PJ, Rassenti L, Barrett CL, Jepsen K, Jamieson CH, Carson D, Kipps TJ, Frazer KA. PMID: 25768983.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansCells
    118. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica. 2015 Aug; 100(8):e311-4. Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmen P, Trnêný M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, Wierda WG, Hx-CD20-406 Study Investigators . PMID: 25769539.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    119. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015 Apr 30; 125(18):2779-85. Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Lymp J, Hirata J, Kipps TJ. PMID: 25769620.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    120. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Res. 2015 May; 39(5):495-500. Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Ghia P, Larson RA, Kipps TJ, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Bühler A, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR. PMID: 25804339.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    121. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2015 Feb 17; 112(7):2169-74. Balatti V, Rizzotto L, Miller C, Palamarchuk A, Fadda P, Pandolfo R, Rassenti LZ, Hertlein E, Ruppert AS, Lozanski A, Lozanski G, Kipps TJ, Byrd JC, Croce CM, Pekarsky Y. PMID: 25646413.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    122. Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget. 2015 Jan 30; 6(3):1884-8. Kämpjärvi K, Järvinen TM, Heikkinen T, Ruppert AS, Senter L, Hoag KW, Dufva O, Kontro M, Rassenti L, Hertlein E, Kipps TJ, Porkka K, Byrd JC, de la Chapelle A, Vahteristo P. PMID: 25595892.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    123. Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther. 2015 Jan; 26(1):14-25. Urquiza M, Melo-Cardenas J, Aguillon R, Kipps TJ, Castro JE. PMID: 25382101.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    124. A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Jun; 56(6):1878-80. Strati P, Tong WG, Vitale C, Wierda WG, O'Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A. PMID: 25311497.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    125. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A. 2014 Dec 02; 111(48):17266-71. Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF, Zhang Z, Wu CC, Chen L, Wu R, Schwab R, Carson DA, Kipps TJ. PMID: 25411317.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansAnimalsCells
    126. Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. Blood Cancer J. 2014 Nov 14; 4:e258. Castro JE, Choi MY, Carvajal T, Almahasnah E, Chang J, James DF, Kipps TJ. PMID: 25397619.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    127. Biased estimates of clonal evolution and subclonal heterogeneity can arise from PCR duplicates in deep sequencing experiments. Genome Biol. 2014 Aug 07; 15(8):420. Smith EN, Jepsen K, Khosroheidari M, Rassenti LZ, D'Antonio M, Ghia EM, Carson DA, Jamieson CH, Kipps TJ, Frazer KA. PMID: 25103687.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    128. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood. 2014 Sep 04; 124(10):1637-44. Fecteau JF, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS, Cathers B, Schwaederlé M, Cui B, Lopez-Girona A, Messmer D, Kipps TJ. PMID: 24990888.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    129. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014 Jul 24; 124(4):546-54. Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, Ghia EM, Zhang L, Bao L, Rassenti LZ, Messer K, Calin GA, Croce CM, Kipps TJ. PMID: 24914134.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCells
    130. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17; 371(3):213-23. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P, RESONATE Investigators . PMID: 24881631.
      View in: PubMed   Mentions: 446     Fields:    Translation:Humans
    131. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol. 2014 Jul 01; 32(19):2067-73. James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ. PMID: 24868031.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    132. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood. 2014 Jul 03; 124(1):42-8. Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC. PMID: 24868078.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    133. Quantitative proteomics to characterize specific histone H2A proteolysis in chronic lymphocytic leukemia and the myeloid THP-1 cell line. Int J Mol Sci. 2014 May 27; 15(6):9407-21. Glibert P, Vossaert L, Van Steendam K, Lambrecht S, Van Nieuwerburgh F, Offner F, Kipps T, Dhaenens M, Deforce D. PMID: 24871368.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    134. Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene. Blood. 2014 Jul 10; 124(2):259-62. Acunzo M, Romano G, Wernicke D, Balatti V, Rassenti LZ, dell'Aquila M, Kipps TJ, Pekarsky Y, Croce CM. PMID: 24855209.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    135. Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. Blood. 2014 Jun 26; 123(26):4101-10. Riches JC, O'Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Werner L, Croce CM, Ramsay AG, Rassenti LZ, Kipps TJ, Gribben JG. PMID: 24829201.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCellsCTClinical Trials
    136. Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma. Electrophoresis. 2014 Jul; 35(12-13):1828-36. Sonnenberg A, Marciniak JY, Skowronski EA, Manouchehri S, Rassenti L, Ghia EM, Widhopf GF, Kipps TJ, Heller MJ. PMID: 24723219.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    137. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood. 2014 Jul 03; 124(1):84-95. Mraz M, Chen L, Rassenti LZ, Ghia EM, Li H, Jepsen K, Smith EN, Messer K, Frazer KA, Kipps TJ. PMID: 24787006.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    138. Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. Leukemia. 2015 Jan; 29(1):86-95. Veronese A, Pepe F, Chiacchia J, Pagotto S, Lanuti P, Veschi S, Di Marco M, D'Argenio A, Innocenti I, Vannata B, Autore F, Marchisio M, Wernicke D, Verginelli F, Leone G, Rassenti LZ, Kipps TJ, Mariani-Costantini R, Laurenti L, Croce CM, Visone R. PMID: 24732594.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    139. Repetition in visual word identification: benefits and costs. Q J Exp Psychol (Hove). 2014 Oct; 67(10):1986-2009. Burt JS, Kipps TJ, Matthews JR. PMID: 25248100.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    140. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014 Feb 20; 506(7488):328-33. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, Kennedy JA, Schimmer AD, Schuh AC, Yee KW, McLeod JL, Doedens M, Medeiros JJ, Marke R, Kim HJ, Lee K, McPherson JD, Hudson TJ, HALT Pan-Leukemia Gene Panel Consortium , Brown AM, Yousif F, Trinh QM, Stein LD, Minden MD, Wang JC, Dick JE. PMID: 24522528.
      View in: PubMed   Mentions: 512     Fields:    Translation:HumansAnimalsCells
    141. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13; 370(11):997-1007. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM. PMID: 24450857.
      View in: PubMed   Mentions: 504     Fields:    Translation:HumansCTClinical Trials
    142. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014 Mar 20; 123(12):1810-7. Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks K, O'Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC. PMID: 24415539.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansCells
    143. ROR1 can interact with TCL1 and enhance leukemogenesis in Eµ-TCL1 transgenic mice. Proc Natl Acad Sci U S A. 2014 Jan 14; 111(2):793-8. Widhopf GF, Cui B, Ghia EM, Chen L, Messer K, Shen Z, Briggs SP, Croce CM, Kipps TJ. PMID: 24379361.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCells
    144. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 2014 Mar; 4(3):348-61. Oakes CC, Claus R, Gu L, Assenov Y, Hüllein J, Zucknick M, Bieg M, Brocks D, Bogatyrova O, Schmidt CR, Rassenti L, Kipps TJ, Mertens D, Lichter P, Döhner H, Stilgenbauer S, Byrd JC, Zenz T, Plass C. PMID: 24356097.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCells
    145. Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. Clin Chem. 2014 Mar; 60(3):500-9. Sonnenberg A, Marciniak JY, Rassenti L, Ghia EM, Skowronski EA, Manouchehri S, McCanna J, Widhopf GF, Kipps TJ, Heller MJ. PMID: 24270796.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    146. Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model. Blood. 2013 Dec 05; 122(24):3960-3. Lascano V, Guadagnoli M, Schot JG, Luijks DM, Guikema JE, Cameron K, Hahne M, Pals S, Slinger E, Kipps TJ, van Oers MH, Eldering E, Medema JP, Kater AP. PMID: 24100449.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    147. The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol. 2014; 9:103-18. Zhang S, Kipps TJ. PMID: 23987584.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    148. Stabilized cyclopropane analogs of the splicing inhibitor FD-895. J Med Chem. 2013 Sep 12; 56(17):6576-82. Villa R, Kashyap MK, Kumar D, Kipps TJ, Castro JE, La Clair JJ, Burkart MD. PMID: 23919277.
      View in: PubMed   Mentions: 7     Fields:    Translation:Cells
    149. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013 Sep 12; 122(11):1891-9. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O'Brien S, Kipps TJ, Keating MJ, Kay NE, Calin GA. PMID: 23821659.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCells
    150. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):568-74. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ, Chronic Lymphocytic Leukemia Research Consortium . PMID: 23810245.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    151. IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope. PLoS One. 2013; 8(6):e65203. Que X, Widhopf GF, Amir S, Hartvigsen K, Hansen LF, Woelkers D, Tsimikas S, Binder CJ, Kipps TJ, Witztum JL. PMID: 23840319.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    152. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res. 2013 Jun 15; 73(12):3649-60. Cui B, Zhang S, Chen L, Yu J, Widhopf GF, Fecteau JF, Rassenti LZ, Kipps TJ. PMID: 23771907.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimalsCells
    153. MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Aug; 54(8):1836-9. Mraz M, Kipps TJ. PMID: 23597135.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    154. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun; 98(6):964-70. Brown JR, Messmer B, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, LaCasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS. PMID: 23645694.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    155. Dielectrophoretic isolation and detection of cfc-DNA nanoparticulate biomarkers and virus from blood. Electrophoresis. 2013 Apr; 34(7):1076-84. Sonnenberg A, Marciniak JY, McCanna J, Krishnan R, Rassenti L, Kipps TJ, Heller MJ. PMID: 23436471.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    156. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A. 2013 Apr 09; 110(15):6127-32. Zhang S, Wu CC, Fecteau JF, Cui B, Chen L, Zhang L, Wu R, Rassenti L, Lao F, Weigand S, Kipps TJ. PMID: 23530247.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    157. Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia. Leukemia. 2013 Apr; 27(5):1214-7. Schwaederlé M, Ghia E, Rassenti LZ, Obara M, Dell'Aquila ML, Fecteau JF, Kipps TJ. PMID: 23337928.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    158. Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia. Blood. 2013 Feb 07; 121(6):971-4. Fecteau JF, Messmer D, Zhang S, Cui B, Chen L, Kipps TJ. PMID: 23255557.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    159. Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. Blood. 2013 Jan 10; 121(2):351-9. Gaudio E, Paduano F, Ngankeu A, Lovat F, Fabbri M, Sun HL, Gasparini P, Efanov A, Peng Y, Zanesi N, Shuaib MA, Rassenti LZ, Kipps TJ, Li C, Aqeilan RI, Lesinski GB, Trapasso F, Croce CM. PMID: 23160471.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    160. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 2012 Dec; 181(6):1903-10. Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, Wu R, Kipps TJ. PMID: 23041612.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansAnimalsCells
    161. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J. 2012 Sep-Oct; 18(5):404-10. Choi MY, Kipps TJ. PMID: 23006944.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    162. Trisomy 12 CLLs progress through NOTCH1 mutations. Leukemia. 2013 Mar; 27(3):740-3. Balatti V, Lerner S, Rizzotto L, Rassenti LZ, Bottoni A, Palamarchuk A, Cascione L, Alder H, Keating MJ, Kipps TJ, Pekarsky Y, Croce CM. PMID: 22902365.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    163. Increased aldehyde dehydrogenase activity in high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Feb; 54(2):400-2. Wu RP, Li H, Rassenti LZ, Hayashi T, Wu CN, Kipps TJ, Messer K, Carson DA. PMID: 22784365.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    164. Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood. 2012 Sep 27; 120(13):2639-49. Chuang HY, Rassenti L, Salcedo M, Licon K, Kohlmann A, Haferlach T, Foà R, Ideker T, Kipps TJ. PMID: 22837534.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    165. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012 Aug 10; 30(23):2820-2. Cheson BD, Byrd JC, Rai KR, Kay NE, O'Brien SM, Flinn IW, Wiestner A, Kipps TJ. PMID: 22778323.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    166. Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. Blood. 2012 Aug 23; 120(8):1687-90. Coombs CC, Rassenti LZ, Falchi L, Slager SL, Strom SS, Ferrajoli A, Weinberg JB, Kipps TJ, Lanasa MC. PMID: 22745306.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    167. The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Blood. 2012 Sep 27; 120(13):2631-8. Tili E, Michaille JJ, Luo Z, Volinia S, Rassenti LZ, Kipps TJ, Croce CM. PMID: 22723551.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    168. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Nov; 53(11):2136-42. Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, O'Brien S. PMID: 22475052.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    169. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol. 2012 Jul 10; 30(20):2483-91. Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Bühler A, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps TJ, Rassenti LZ, Gribben JG, Döhner H, Heerema NA, Marcucci G, Plass C, Byrd JC. PMID: 22564988.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    170. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res. 2012 Jun 15; 72(12):2937-48. Castro JE, Melo-Cardenas J, Urquiza M, Barajas-Gamboa JS, Pakbaz RS, Kipps TJ. PMID: 22505652.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    171. Chronic lymphocytic leukemia associated with immunotactoid glomerulopathy: a case report of successful treatment with high-dose methylprednisolone in combination with rituximab followed by alemtuzumab. Leuk Lymphoma. 2012 Sep; 53(9):1835-8. Castro JE, Diaz-Perez JA, Barajas-Gamboa JS, Horton JM, Weidner N, Kipps TJ. PMID: 22335532.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    172. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One. 2012; 7(3):e31127. Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, Tang L, Chen G, Basak GW, Kipps TJ. PMID: 22403610.
      View in: PubMed   Mentions: 105     Fields:    Translation:HumansAnimalsCells
    173. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol Med. 2012 Feb 10; 18:19-28. Fecteau JF, Bharati IS, O'Hayre M, Handel TM, Kipps TJ, Messmer D. PMID: 21979753.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    174. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 2012 Feb 14; 109(7):2555-60. Palamarchuk A, Yan PS, Zanesi N, Wang L, Rodrigues B, Murphy M, Balatti V, Bottoni A, Nazaryan N, Alder H, Rassenti L, Kipps TJ, Freitas M, Croce CM, Pekarsky Y. PMID: 22308499.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    175. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Blood. 2012 Mar 08; 119(10):2293-301. Steininger C, Widhopf GF, Ghia EM, Morello CS, Vanura K, Sanders R, Spector D, Guiney D, Jäger U, Kipps TJ. PMID: 22234695.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    176. Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. Front Biosci (Schol Ed). 2012 Jan 01; 4:61-73. Fecteau JF, Kipps TJ. PMID: 22202043.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    177. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012 Feb 10; 30(5):488-96. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R. PMID: 22184378.
      View in: PubMed   Mentions: 295     Fields:    Translation:HumansCTClinical Trials
    178. NOTCH1 mutations in CLL associated with trisomy 12. Blood. 2012 Jan 12; 119(2):329-31. Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ, Pekarsky Y, Croce CM. PMID: 22086416.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCells
    179. Tcl1 interacts with Atm and enhances NF-?B activation in hematologic malignancies. Blood. 2012 Jan 05; 119(1):180-7. Gaudio E, Spizzo R, Paduano F, Luo Z, Efanov A, Palamarchuk A, Leber AS, Kaou M, Zanesi N, Bottoni A, Costinean S, Rassenti LZ, Nakamura T, Kipps TJ, Aqeilan RI, Pekarsky Y, Trapasso F, Croce CM. PMID: 22065599.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimals
    180. ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk Res. 2011 Oct; 35(10):1390-4. Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ. PMID: 21813176.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    181. Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease. J Hum Genet. 2011 Sep; 56(9):676-81. Peiró AM, Tang CM, Murray F, Zhang L, Brown LM, Chou D, Rassenti L, Kipps TJ, Kipps TA, Insel PA. PMID: 21796143.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    182. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 09; 108(32):13253-7. Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. PMID: 21788521.
      View in: PubMed   Mentions: 131     Fields:    Translation:HumansCells
    183. IRF4 mutations in chronic lymphocytic leukemia. Blood. 2011 Sep 08; 118(10):2827-9. Havelange V, Pekarsky Y, Nakamura T, Palamarchuk A, Alder H, Rassenti L, Kipps T, Croce CM. PMID: 21791429.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    184. Rituximab in chronic lymphocytic leukemia. Adv Ther. 2011 Jul; 28(7):534-54. James DF, Kipps TJ. PMID: 21725721.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    185. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood. 2011 Sep 15; 118(11):3072-9. Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M, Volinia S, Taccioli C, Kipps TJ, Croce CM. PMID: 21636858.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    186. Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia. Leuk Res. 2011 Jul; 35(7):965-7. Messmer BT, Nour-Omid TS, Ghia E, Sanchez AB, Kipps TJ. PMID: 21570119.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    187. Analyses of recombinant stereotypic IGHV3-21-encoded antibodies expressed in chronic lymphocytic leukemia. J Immunol. 2011 Jun 01; 186(11):6338-44. Ghia EM, Widhopf GF, Rassenti LZ, Kipps TJ. PMID: 21525382.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    188. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011 Jun 16; 117(24):6450-8. Wierda WG, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Gorczyca M, Chang CN, Chan G, Gupta I, Nielsen TG, Russell CA, 407 Study Investigators . PMID: 21498674.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    189. Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia. Eur J Haematol. 2011 May; 86(5):405-411. Buhl AM, James DF, Neuberg D, Jain S, Rassenti LZ, Kipps TJ. PMID: 21323738.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    190. Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia. Int J Cancer. 2011 Sep 01; 129(5):1162-9. Zhang L, Murray F, Rassenti LZ, Pu M, Kelly C, Kanter JR, Greaves A, Messer K, Kipps TJ, Insel PA. PMID: 21120911.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    191. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011 Jan 05; 305(1):59-67. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell'Aquila M, Alder H, Davuluri RV, Rassenti LZ, Negrini M, Nakamura T, Amadori D, Kay NE, Rai KR, Keating MJ, Kipps TJ, Calin GA, Croce CM. PMID: 21205967.
      View in: PubMed   Mentions: 117     Fields:    Translation:HumansCells
    192. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. Cancer Genet Cytogenet. 2010 Dec; 203(2):134-40. Heerema NA, Byrd JC, Dal Cin PS, Dell' Aquila ML, Koduru PR, Aviram A, Smoley SA, Rassenti LZ, Greaves AW, Brown JR, Rai KR, Kipps TJ, Kay NE, Van Dyke DL, Chronic Lymphocytic Leukemia Research Consortium . PMID: 21156225.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    193. Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. Cancer Genet Cytogenet. 2010 Dec; 203(2):141-8. Smoley SA, Van Dyke DL, Kay NE, Heerema NA, Dell' Aquila ML, Dal Cin P, Koduru P, Aviram A, Rassenti L, Byrd JC, Rai KR, Brown JR, Greaves AW, Eckel-Passow J, Neuberg D, Kipps TJ, Dewald GW. PMID: 21156226.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    194. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet. 2010 Dec; 203(2):161-8. Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL, Jelinek DF, Tschumper RC, Kipps T, Byrd JC, Fonseca R. PMID: 21156228.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    195. CCL3 (MIP-1a) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011 Feb 03; 117(5):1662-9. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. PMID: 21115978.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    196. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood. 2011 Jan 20; 117(3):882-9. Messmer D, Fecteau JF, O'Hayre M, Bharati IS, Handel TM, Kipps TJ. PMID: 21079155.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    197. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2010 Nov 02; 107(44):18956-60. Zhang W, Kater AP, Widhopf GF, Chuang HY, Enzler T, James DF, Poustovoitov M, Tseng PH, Janz S, Hoh C, Herschman H, Karin M, Kipps TJ. PMID: 20956327.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    198. Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. Br J Haematol. 2010 Nov; 151(4):336-45. Setlur SR, Ihm C, Tchinda J, Shams S, Werner L, Cho EK, Thompson C, Phillips K, Rassenti LZ, Kipps TJ, Neuberg D, Freedman AS, Lee C, Brown JR. PMID: 20812997.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    199. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer. 2011 Jan 01; 117(1):116-24. Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O'Brien SM, CLL Research Consortium . PMID: 20806349.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    200. Clinical roundtable monograph. New alternatives in CLL therapy: managing adverse events. Clin Adv Hematol Oncol. 2010 Aug; 8(8):suppl 1-15. Chanan-Khan A, Kipps T, Stilgenbauer S. PMID: 21192630.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    201. Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. PLoS One. 2010 Jul 22; 5(7):e11716. O'Hayre M, Salanga CL, Kipps TJ, Messmer D, Dorrestein PC, Handel TM. PMID: 20661426.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    202. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A. 2010 Jul 06; 107(27):12210-5. Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, Volinia S, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. PMID: 20566844.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansAnimalsCells
    203. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010 May; 20(5):589-99. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM. PMID: 20439436.
      View in: PubMed   Mentions: 156     Fields:    Translation:HumansAnimalsCells
    204. Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. Int J Clin Exp Pathol. 2010 Apr 23; 3(4):448-57. Du S, Rashidi HH, Le DT, Kipps TJ, Broome HE, Wang HY. PMID: 20490336.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    205. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010 May 20; 28(15):2529-37. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Béné MC, De Vos J, Hernández JM, Hofmann WK, Mills KI, Gilkes A, Chiaretti S, Shurtleff SA, Kipps TJ, Rassenti LZ, Yeoh AE, Papenhausen PR, Liu WM, Williams PM, Foà R. PMID: 20406941.
      View in: PubMed   Mentions: 243     Fields:    Translation:Humans
    206. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010 Aug 12; 116(6):945-52. Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA. PMID: 20393129.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCells
    207. Chemical biology strategy reveals pathway-selective inhibitor of NF-kappaB activation induced by protein kinase C. ACS Chem Biol. 2010 Mar 19; 5(3):287-99. Shi R, Re D, Dudl E, Cuddy M, Okolotowicz KJ, Dahl R, Su Y, Hurder A, Kitada S, Peddibhotla S, Roth GP, Smith LH, Kipps TJ, Cosford N, Cashman J, Reed JC. PMID: 20141195.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    208. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 01; 28(10):1749-55. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A, Hx-CD20-406 Study Investigators . PMID: 20194866.
      View in: PubMed   Mentions: 172     Fields:    Translation:HumansCTClinical Trials
    209. A general process for the development of peptide-based immunoassays for monoclonal antibodies. Cancer Chemother Pharmacol. 2010 Oct; 66(5):919-25. Sanchez AB, Nguyen T, Dema-Ala R, Kummel AC, Kipps TJ, Messmer BT. PMID: 20087593.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    210. 13q14 deletions in CLL involve cooperating tumor suppressors. Blood. 2010 May 13; 115(19):3916-22. Palamarchuk A, Efanov A, Nazaryan N, Santanam U, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. PMID: 20071661.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    211. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One. 2009 Dec 14; 4(12):e8294. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, Schmidt-Wolf IG, Kipps TJ, Carson DA. PMID: 20011538.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    212. Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis. 2010 Feb; 31(2):208-15. Wojcik SE, Rossi S, Shimizu M, Nicoloso MS, Cimmino A, Alder H, Herlea V, Rassenti LZ, Rai KR, Kipps TJ, Keating MJ, Croce CM, Calin GA. PMID: 19926640.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    213. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2010 Jan 21; 115(3):489-95. Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S. PMID: 19843887.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    214. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood. 2009 Nov 12; 114(20):4469-76. Enzler T, Kater AP, Zhang W, Widhopf GF, Chuang HY, Lee J, Avery E, Croce CM, Karin M, Kipps TJ. PMID: 19755673.
      View in: PubMed   Mentions: 29     Fields:    Translation:Animals
    215. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood. 2009 Oct 29; 114(18):3872-9. Visone R, Rassenti LZ, Veronese A, Taccioli C, Costinean S, Aguda BD, Volinia S, Ferracin M, Palatini J, Balatti V, Alder H, Negrini M, Kipps TJ, Croce CM. PMID: 19717645.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCells
    216. Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell. 2009 Aug 04; 16(2):161-71. Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, Yasudo H, Kimura A, Kubagawa H, Bertoli LF, Davis RS, Chau LA, Madrenas J, Hsia CC, Xenocostas A, Kipps TJ, Hennighausen L, Iwama A, Nakauchi H, Kawakami T. PMID: 19647226.
      View in: PubMed   Mentions: 34     Fields:    Translation:AnimalsCells
    217. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci U S A. 2008 Dec 16; 105(50):19643-8. Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U, Rassenti L, Kipps T, Croce CM. PMID: 19064921.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCells
    218. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood. 2009 Apr 02; 113(14):3168-71. Lin KI, Tam CS, Keating MJ, Wierda WG, O'Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron LL, Kipps TJ, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV. PMID: 19050308.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    219. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2008 Dec 09; 105(49):19532-7. Zhang L, Murray F, Zahno A, Kanter JR, Chou D, Suda R, Fenlon M, Rassenti L, Cottam H, Kipps TJ, Insel PA. PMID: 19033455.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    220. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009 Jan 08; 113(2):299-305. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. PMID: 18931344.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCTClinical Trials
    221. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. Br J Haematol. 2008 Sep; 142(5):802-7. Kohlmann A, Kipps TJ, Rassenti LZ, Downing JR, Shurtleff SA, Mills KI, Gilkes AF, Hofmann WK, Basso G, Dell'orto MC, Foà R, Chiaretti S, De Vos J, Rauhut S, Papenhausen PR, Hernández JM, Lumbreras E, Yeoh AE, Koay ES, Li R, Liu WM, Williams PM, Wieczorek L, Haferlach T. PMID: 18573112.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    222. Genomic complexity in chronic lymphocytic leukemia. Blood. 2008 Sep 01; 112(5):1550. Kipps TJ. PMID: 18725569.
      View in: PubMed   Mentions: 1     Fields:    
    223. Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res. 2009 Mar; 33(3):368-76. Messmer BT, Raphael BJ, Aerni SJ, Widhopf GF, Rassenti LZ, Gribben JG, Kay NE, Kipps TJ. PMID: 18640719.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    224. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008 Sep 01; 112(5):1923-30. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. PMID: 18577710.
      View in: PubMed   Mentions: 110     Fields:    Translation:Humans
    225. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A. 2008 Apr 01; 105(13):5166-71. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S, Rassenti L, Liu X, Liu CG, Kipps TJ, Negrini M, Croce CM. PMID: 18362358.
      View in: PubMed   Mentions: 285     Fields:    Translation:HumansAnimalsCells
    226. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008 May 15; 111(10):5101-8. Ghia EM, Jain S, Widhopf GF, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. PMID: 18326815.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    227. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A. 2008 Feb 26; 105(8):3047-52. Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, Widhopf GF, Rassenti LZ, Cantwell MJ, Prussak CE, Carson DA, Kipps TJ. PMID: 18287027.
      View in: PubMed   Mentions: 130     Fields:    Translation:HumansAnimalsCells
    228. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15; 111(12):5446-56. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic Leukemia . PMID: 18216293.
      View in: PubMed   Mentions: 997     Fields:    Translation:Humans
    229. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. PMID: 18182662.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    230. MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br J Haematol. 2007 Dec; 139(5):709-16. Nicoloso MS, Kipps TJ, Croce CM, Calin GA. PMID: 18021085.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimals
    231. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood. 2008 Mar 01; 111(5):2685-92. Chen L, Huynh L, Apgar J, Tang L, Rassenti L, Weiss A, Kipps TJ. PMID: 18048647.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCells
    232. Value of computed tomography in the monitoring of patients with chronic lymphocytic leukemia. J Clin Oncol. 2007 Dec 10; 25(35):5556. Kipps TJ. PMID: 17984183.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    233. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol. 2007 Sep; 20(3):557-68. Wierda WG, Kipps TJ. PMID: 17707840.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    234. The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 2007 Sep; 20(3):415-24. Kipps TJ. PMID: 17707830.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    235. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 2007 Sep; 12(3):215-29. Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, Fabbri M, Cimmino A, Lee EJ, Wojcik SE, Shimizu M, Tili E, Rossi S, Taccioli C, Pichiorri F, Liu X, Zupo S, Herlea V, Gramantieri L, Lanza G, Alder H, Rassenti L, Volinia S, Schmittgen TD, Kipps TJ, Negrini M, Croce CM. PMID: 17785203.
      View in: PubMed   Mentions: 307     Fields:    Translation:HumansCells
    236. A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood. 2007 Nov 01; 110(9):3326-33. Sellick GS, Goldin LR, Wild RW, Slager SL, Ressenti L, Strom SS, Dyer MJ, Mauro FR, Marti GE, Fuller S, Lyttelton M, Kipps TJ, Keating MJ, Call TG, Catovsky D, Caporaso N, Houlston RS. PMID: 17687107.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    237. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood. 2008 Mar 15; 111(6):3137-44. Widhopf GF, Goldberg CJ, Toy TL, Rassenti LZ, Wierda WG, Byrd JC, Keating MJ, Gribben JG, Rai KR, Kipps TJ. PMID: 17675554.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    238. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 1):4448-55. Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S. PMID: 17671129.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    239. Cellular immune therapy for chronic lymphocytic leukemia. Blood. 2007 Oct 15; 110(8):2811-8. Kater AP, van Oers MH, Kipps TJ. PMID: 17638850.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    240. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell. 2007 Jun 01; 129(5):879-90. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, Hackanson B, Grever MR, Lucas DM, Matkovic JJ, Lin TS, Kipps TJ, Murray F, Weisenburger D, Sanger W, Lynch J, Watson P, Jansen M, Yoshinaga Y, Rosenquist R, de Jong PJ, Coggill P, Beck S, Lynch H, de la Chapelle A, Plass C. PMID: 17540169.
      View in: PubMed   Mentions: 138     Fields:    Translation:HumansAnimalsCells
    241. Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Exp Hematol. 2007 Mar; 35(3):434-42. Kato K, Chu P, Takahashi S, Hamada H, Kipps TJ. PMID: 17309824.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    242. Alemtuzumab in chronic lymphocytic leukemia. Future Oncol. 2007 Feb; 3(1):29-42. James DF, Kipps TJ. PMID: 17280499.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    243. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006 Dec 15; 66(24):11590-3. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM. PMID: 17178851.
      View in: PubMed   Mentions: 251     Fields:    Translation:HumansCells
    244. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood. 2007 Jan 15; 109(2):703-10. Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF, Karin M, Kipps TJ. PMID: 16973958.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCells
    245. Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2006 Jul 15; 70(4):209-13. Rassenti LZ, Kipps TJ. PMID: 16906583.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    246. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood. 2006 Nov 15; 108(10):3450-7. Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G, Wang JY, Kipps TJ. PMID: 16741250.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    247. CD154 gene therapy for human B-cell malignancies. Ann N Y Acad Sci. 2005 Dec; 1062:51-60. Messmer D, Kipps TJ. PMID: 16461788.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    248. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006 Mar 01; 107(5):1761-7. Burger JA, Kipps TJ. PMID: 16269611.
      View in: PubMed   Mentions: 397     Fields:    Translation:HumansAnimalsCells
    249. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res. 2005 Nov; 29(11):1253-7. Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K, Petric R, Ramon-Suerez J, Gabrilove J, Grever MR. PMID: 15916806.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    250. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005 Oct 27; 353(17):1793-801. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. PMID: 16251535.
      View in: PubMed   Mentions: 873     Fields:    Translation:HumansCells
    251. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 2006 Feb 01; 107(3):859-61. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Döhner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ, Rai K, International Workshop on Chronic Lymphocytic Leukemia (IWCLL) . PMID: 16223776.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    252. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005 Sep 27; 102(39):13944-9. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. PMID: 16166262.
      View in: PubMed   Mentions: 1307     Fields:    Translation:HumansCells
    253. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol. 2005 Sep 10; 23(26):6325-32. Wierda WG, Kipps TJ, Keating MJ. PMID: 16155015.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    254. Treatment of solid tumors with immunotoxins. Breast Cancer Res. 2005; 7(5):184-6. Messmer D, Kipps TJ. PMID: 16168135.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    255. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood. 2005 Oct 01; 106(7):2506-12. Castro JE, Prada CE, Loria O, Kamal A, Chen L, Burrows FJ, Kipps TJ. PMID: 15972449.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    256. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood. 2005 Sep 01; 106(5):1742-8. Kater AP, Dicker F, Mangiola M, Welsh K, Houghten R, Ostresh J, Nefzi A, Reed JC, Pinilla C, Kipps TJ. PMID: 15914559.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    257. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005 Sep 01; 106(5):1824-30. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA. PMID: 15905192.
      View in: PubMed   Mentions: 98     Fields:    Translation:HumansCells
    258. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood. 2005 Aug 01; 106(3):1012-20. Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, Reed JC, Zvaifler NJ, Kipps TJ. PMID: 15860672.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCells
    259. Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med. 2005 Apr 21; 352(16):1667-76. Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H, Mabuchi H, Shiraishi T, Hansen LL, Overgaard J, Herlea V, Mauro FR, Dighiero G, Movsas B, Rassenti L, Kipps T, Baffa R, Fusco A, Mori M, Russo G, Liu CG, Neuberg D, Bullrich F, Negrini M, Croce CM. PMID: 15843669.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    260. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 10; 23(17):3877-85. Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, Rassenti L, Kipps TJ, Grever MR, Byrd JC, Plass C. PMID: 15809452.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    261. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol. 2005 Jan 15; 174(2):864-70. Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA, Kipps TJ. PMID: 15634908.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    262. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood. 2005 Mar 01; 105(5):2036-41. Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L, Weiss A, Kipps TJ. PMID: 15514014.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    263. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004 Sep 01; 101(5):999-1008. Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM, Keating M. PMID: 15329909.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    264. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood. 2005 Apr 15; 105(8):3193-8. Dicker F, Kater AP, Fukuda T, Kipps TJ. PMID: 15339846.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    265. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004 Aug 26; 351(9):893-901. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. PMID: 15329427.
      View in: PubMed   Mentions: 242     Fields:    Translation:HumansCells
    266. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004 Aug 10; 101(32):11755-60. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM. PMID: 15284443.
      View in: PubMed   Mentions: 432     Fields:    Translation:HumansCells
    267. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood. 2004 Oct 15; 104(8):2499-504. Widhopf GF, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. PMID: 15217828.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCells
    268. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol. 2004 Mar; 11(3):389-95. Becattini B, Kitada S, Leone M, Monosov E, Chandler S, Zhai D, Kipps TJ, Reed JC, Pellecchia M. PMID: 15123268.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    269. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2004 Mar 02; 101(9):3118-23. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps TJ, Corr M, Carson DA. PMID: 14973184.
      View in: PubMed   Mentions: 140     Fields:    Translation:HumansCells
    270. Transgenic expression of a human polyreactive Ig expressed in chronic lymphocytic leukemia generates memory-type B cells that respond to nonspecific immune activation. J Immunol. 2004 Feb 15; 172(4):2092-9. Widhopf GF, Brinson DC, Kipps TJ, Tighe H. PMID: 14764674.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    271. Retraction: The triterpenoid CDDO-Imidazolide induces apoptosis and enhances fludarabine-induced apoptosis of CLL B-cells. Blood. 2004 Aug 15; 104(4):932. Pedersen IM, Zapata JM, Samuel T, Scott FL, Salvesen GS, Honda T, Gribble GW, Suh N, Sporn MB, Kipps TJ, Reed JC. PMID: 14739219.
      View in: PubMed   Mentions:    Fields:    
    272. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene. 2003 Nov 06; 22(50):8093-101. Burger M, Glodek A, Hartmann T, Schmitt-Gräff A, Silberstein LE, Fujii N, Kipps TJ, Burger JA. PMID: 14603250.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansAnimalsCells
    273. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res. 2003 Jul 15; 63(14):4128-35. Rieger R, Kipps TJ. PMID: 12874017.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    274. Immunobiology of chronic lymphocytic leukemia. Curr Opin Hematol. 2003 Jul; 10(4):312-8. Kipps TJ. PMID: 12799538.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    275. Selection of oligonucleotide aptamers with enhanced uptake and activation of human leukemia B cells. Hum Gene Ther. 2003 Jun 10; 14(9):849-60. Wu CC, Castro JE, Motta M, Cottam HB, Kyburz D, Kipps TJ, Corr M, Carson DA. PMID: 12828856.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    276. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. Clin Cancer Res. 2003 Jun; 9(6):2166-72. Battle TE, Wierda WG, Rassenti LZ, Zahrieh D, Neuberg D, Kipps TJ, Frank DA. PMID: 12796382.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    277. CRC Tissue Core Management System (TCMS): integration of basic science and clinical data for translational research. AMIA Annu Symp Proc. 2003; 853. Greaves AW, Payne PR, Rassenti L, Kipps TJ. PMID: 14728358.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    278. Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2003; 153-75. Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR, Ferrarini M, Kipps TJ. PMID: 14633781.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    279. CRC Clinical Trials Management System (CTMS): an integrated information management solution for collaborative clinical research. AMIA Annu Symp Proc. 2003; 967. Payne PR, Greaves AW, Kipps TJ. PMID: 14728471.
      View in: PubMed   Mentions: 7     Fields:    
    280. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002 Nov 26; 99(24):15524-9. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. PMID: 12434020.
      View in: PubMed   Mentions: 1675     Fields:    Translation:HumansCells
    281. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood. 2002 Oct 15; 100(8):2965-72. Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L, Rassenti L, Andreeff M, Bennett F, Sporn MB, Liotta LD, Kipps TJ, Reed JC. PMID: 12351409.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    282. HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia. Mol Ther. 2002 Oct; 6(4):455-63. Tolba KA, Bowers WJ, Eling DJ, Casey AE, Kipps TJ, Federoff HJ, Rosenblatt JD. PMID: 12377186.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    283. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood. 2002 Sep 01; 100(5):1795-801. Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, Tsukada N, Kipps TJ, Choi YS, Bennett F, Reed JC. PMID: 12176902.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCells
    284. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002 Dec 15; 100(13):4609-14. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, Kipps TJ. PMID: 12393534.
      View in: PubMed   Mentions: 127     Fields:    Translation:HumansCells
    285. Immune and cell therapy of hematologic malignancies. Int J Hematol. 2002 Aug; 76 Suppl 1:269-73. Kipps TJ. PMID: 12430862.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    286. Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells. Br J Haematol. 2002 Aug; 118(2):506-13. Bashey A, Cantwell MJ, Kipps TJ. PMID: 12139739.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    287. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002 Mar 19; 99(6):3854-9. Chu P, Deforce D, Pedersen IM, Kim Y, Kitada S, Reed JC, Kipps TJ. PMID: 11891278.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    288. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002 Mar; 43(3):461-6. Burger JA, Kipps TJ. PMID: 12002747.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    289. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002 Feb 01; 99(3):1030-7. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. PMID: 11807009.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCells
    290. Advances in classification and therapy of indolent B-cell malignancies. Semin Oncol. 2002 Feb; 29(1 Suppl 2):98-104. Kipps TJ. PMID: 11842396.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    291. Advances in classification and therapy of indolent B-cell malignancies. Semin Oncol. 2002 Feb; 29(1S2):98-104. Kipps TJ. PMID: 28140099.
      View in: PubMed   Mentions: 2     Fields:    
    292. Sequential modulation of growth factors: a novel strategy for adoptive immunotherapy of acute myeloid leukemia. Biol Blood Marrow Transplant. 2002; 8(10):557-68. Zhong RK, Rassenti LZ, Kipps TJ, Chen J, Law P, Yu JF, Ball ED. PMID: 12434951.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells